At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRVO CervoMed
Market Closed 02-14 16:00:00 EST
2.33
+0.14
+6.39%
盘后2.36
+0.03+1.29%
17:50 EST
High2.37Low2.20Vol125.79K
Open2.21D1 Closing2.19Amplitude7.68%
Mkt Cap19.23MTradable Cap10.56MTotal Shares8.25M
T/O291.61KT/O Rate2.78%Tradable Shares4.53M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
CervoMed Updates on Neflamapimod Trials for Dementia
TIPRANKS  ·  01-31
CervoMed Updates on Neflamapimod Trials for Dementia
CervoMed Provides Update on Neflamapimod Dlb Program as Part of Presentation at the 8TH International Lewy Body Dementia Conference
THOMSON REUTERS  ·  01-31
CervoMed Provides Update on Neflamapimod Dlb Program as Part of Presentation at the 8TH International Lewy Body Dementia Conference
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
GlobeNewswire  ·  01-31
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
CervoMed to Present at the 8th International Lewy Body Dementia Conference
GlobeNewswire  ·  01-29
CervoMed to Present at the 8th International Lewy Body Dementia Conference
HC Wainwright Downgrades CervoMed to Neutral From Buy
MT Newswires Live  ·  2024-12-17
HC Wainwright Downgrades CervoMed to Neutral From Buy
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
GlobeNewswire  ·  2024-12-17
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
CervoMed Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones  ·  2024-12-17
CervoMed Cut to Neutral From Buy by HC Wainwright & Co.
CervoMed (CRVO) was downgraded to a Hold Rating at H.C. Wainwright
TIPRANKS  ·  2024-12-17
CervoMed (CRVO) was downgraded to a Hold Rating at H.C. Wainwright
CervoMed downgraded to Neutral from Buy at H.C. Wainwright
TIPRANKS  ·  2024-12-17
CervoMed downgraded to Neutral from Buy at H.C. Wainwright
CervoMed Inc : H.c. Wainwright Cuts to Neutral From Buy
THOMSON REUTERS  ·  2024-12-17
CervoMed Inc : H.c. Wainwright Cuts to Neutral From Buy
CervoMed price target lowered to $4 from $45 at Roth MKM
TipRanks  ·  2024-12-12
CervoMed price target lowered to $4 from $45 at Roth MKM
CervoMed announces inducement grants under Nasdaq lisitng rule
TIPRANKS  ·  2024-12-12
CervoMed announces inducement grants under Nasdaq lisitng rule
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  2024-12-12
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  2024-12-12
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Morgan Stanley Downgrades CervoMed to Underweight From Overweight
MT Newswires Live  ·  2024-12-11
Morgan Stanley Downgrades CervoMed to Underweight From Overweight
CervoMed downgraded to Underweight from Overweight at Morgan Stanley
TIPRANKS  ·  2024-12-11
CervoMed downgraded to Underweight from Overweight at Morgan Stanley
Morgan Stanley downgrades CervoMed (CRVO) to a Sell
TIPRANKS  ·  2024-12-11
Morgan Stanley downgrades CervoMed (CRVO) to a Sell
CervoMed downgraded to Neutral from Buy at Chardan
TIPRANKS  ·  2024-12-11
CervoMed downgraded to Neutral from Buy at Chardan
Sector Update: Health Care Stocks Decline Late Afternoon
MT Newswires Live  ·  2024-12-11
Sector Update: Health Care Stocks Decline Late Afternoon
Sector Update: Health Care Stocks Softer Tuesday Afternoon
MT Newswires Live  ·  2024-12-11
Sector Update: Health Care Stocks Softer Tuesday Afternoon

Introduction

Company Name.
CervoMed
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Issue price:
--